Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICGeneric

VASOCIDIN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

Standard Dose
EQ 0.23% PHOSPHATE;10% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview VASOCIDIN is listed in Drugs@FDA under application 018988 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM Form and strength SOLUTION/DROPS;OPHTHALMIC - EQ 0.23% PHOSPHATE;10% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor NOVARTIS Submission history Latest submission status date: 2000-12-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview VASOCIDIN is listed in Drugs@FDA under application 018988 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM Form and strength SOLUTION/DROPS;OPHTHALMIC - EQ 0.23% PHOSPHATE;10% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor NOVARTIS Submission history Latest submission status date: 2000-12-26 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.